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In view of the frequent activation of the epidennal growth factor receptor (EGF-R) in gliomas and autocrine hypothesis, we searched for ‘EGF-like’ 
factor(s) in cystic fluids (CFs) associated with gliomas. Membranes of A431 cells, which overexpress EGF-R, were used to explore such activity 
in 20 CFs. In all cases CFs induced inhibition of EGF-R phosphorylation. Biochemical analysis revealed an anti-tyrosine kinase activity which 
was identified as a 18 kDa proteic factor. Effectiveness at high dilution and anti-proliferative ffect on living cells in culture suggest hat this factor 
may be involved in the negative regulation of glial oncogenesis. 
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1. INTRODUCTION 2. MATERIALS AND METHODS 
Brain tumors of which 60% are gliomas, account for 
almost 8% of human malignancies. These tumors are 
characterized by their poor and almost always fatal 
prognosis [l]. During the last decade, the new concept 
of oncogenes, and more recently of anti-oncogenes, has 
brought new perspectives for a better understanding of 
the mechanisms of the disease and therefore for new 
therapeutic weapons [2]. 
The proto-oncogene c-erbB encoding the epidermal 
growth factor receptor (EGF-R), appears to be involved 
in at least 40% of gliomas [3-71. EGF-R is a 170 kDa 
membrane glycoprotein which contains 3 domains in- 
cluding an intracellular one with tyrosine kinase activ- 
ity. EGF and TGF-a are the principle related polypep- 
tide growth factors. Intrinsic tyrosine kinase activity is 
essential in the signal transduction of EGF, resulting in 
cellular proliferation (for review see [8 and 91). 
The interest in cystic fluid (CF) came from its privi- 
leged and direct relationship with the tumor, the biology 
of which could be specifically reflected in the fluid 
formed from their tissues. In view of the frequent activa- 
tion of EGF-R in gliomas and autocrine hypothesis [lo], 
we searched for ‘EGF-like’ factor(s) in CF. 
Contrary to the expected result, we observed in CFs 
an inhibitory activity of EGF-R autophosphorylation. 
Identification and characterization of the related factor 
are reported. 
Correspondence address: A.L. Benabid, INSERM U. 318, CHU 
Grenoble, 38000 Grenoble BP 217X, France. 
2.1. Cystic fluids ( CFs) 
CFs were obtained from patients admitted to the Neurosurgery 
department of the University Hospital of Grenoble. Most of them 
were obtained by aspiration during stereotaxic investigation for bi- 
opsy sampling. Each sample was immediately frozen in liquid nitro- 
gen. Neuropathological diagnosis of the associated tumor was as- 
sessed in paraffin-embedded tissues obtained by stereotaxic biopsy. 20 
CFs were studied: 10 associated with grade I-II, 7 with grade III and 
3 with grade IV astrocytomas. 
2.2. EGF receptor phosphorylation assay 
EGF-R phosphorylation was analyzed using membranes from 
A431 cells which are known to overexpress this receptor [ll]. After 
purification A431 membranes were homogenized in buffer containing 
20 mM HEPES (pH 7.4), 1.5 mM MgCl,, 1 mM EGTA, 10 &ml 
leupeptine, 1 mM PMSF and 1% Triton X-100. Phosphorylation was 
performed with 15 mM MgCl, and 2O&ml leupeptine in the presence 
or absence of EGF (2 FM) and CF for 10 min at 4°C. Self-phospho- 
rylation was allowed to proceed for 10 min at 4°C with 10 mM MgCl, 
and 2 @Zi [y-‘2P]ATP. The phosphorylation reaction was stopped by 
adding 30 ~1 of Laemmli buffer [12]. The effects of heat denaturation, 
trypsin digestion, influence of vanadate (inhibitor of tyrosine phos- 
phatase) and previous immunoabsorption with an antibody against 
the extracellular domain of EGF-R (Amersham) were analyzed. Sam- 
ples were electrophoresed on 7.5% SDS-PAGE, dried and exposed to 
AGFA XRPl film. EGF-R phosphorylation was quantified by Cer- 
enkov effect on the radioactive band detected at 170 kDa by auto- 
radiography. 
2.3. Phosphoamino acid analysis 
EGF-R phosphorylation was performed as described above in the 
absence of EGF, in the presence of EGF (2 PM) and in the presence 
of EGF and CF. The gel fragment containing phosphorylated EGF-R 
was cut out, washed overnight in 20% methanol at 37°C and incubated 
with 100 &ml of trypsin for 24 h. Eluted peptides were hydrolysed 
2 h in 6 N HCl at 1lO’C. Resultant phosphoamino acids were electro- 
phoresed on a thin-layer cellulose plate and subjected to autoradiogra- 
phy. Unlabeled standards added to the phosphoamino acids were 
visualized with ninhydrin spray. 
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2.4. In viva phosphorylation assa.v 
The biochemical effect obtained on A431 cells membranes was 
analyzed in whole cells in culture on A 431 cell line, a human vulva 
carcinoma cell line, and in the GHD cell line, a human glioma cell line, 
in which EGF-R mRNA is hyperexpressed and the related protein 
hyperphosphorylated. Cells were cultured in 50% DMEM and 50% 
F12 supplemented with 10% fetal calf serum or 10% CF. In vivo 
proteic patterns were analyzed by the”incorporation of [‘*P]ortho- 
phosphate in the presence or absence of CF. Labelling was performed 
for 12 h. After two washes, cells were homogenized in buffer contain- 
ing 9.5 M urea. 2% Nonidet 40 (v/v), 5% /3-mercaptoethanol (v/v), 2% 
Ampholines 3.5-9.5 (Pharmacia) (v/v). Samples were then subjected 
to bidimensional electrophoresis. 
2.5. Bidimensional electrophoresis 
Bidimensional electrophoresis was performed according to O’Farrel 
[12] with minor modifications using Ampholites 3.5-9.5 (Pharmacia). 
After equdibration in Laemmli buffer [13] the second SDS-PAGE 
dimension was performed in a 7.5% acrylamide gel using a mini-gel- 
apparatus (Bio-Rad). 
2 6. Chromatograph?’ 
Crude cystic fluid was separated on Superose 12 into 8 fractions 
corresponding to proteic peaks detected by absorbance at 280 nm. An 
aliquot (50 ~1) of each fraction was then analyzed for its inhibitory 
effect on EGF-R phosphorylation without concentration. 
2.7 Protein purification by preparative protein blotting 
Cystic fluid were absorbed on a Hitrap blue (Pharmacia) column 
to eliminate albumin and apply more protein on the polyacrylamide 
gel. Resultant proteins were separated by SDS-PAGE on 15% (w/v) 
polyacrylamide gels. After running, proteins were transferred to Im- 
mobilon P (Millipore) in a transfer buffer of 20 mM Tris, 150 mM 
glycine, and 20% (v/v) methanol. Protein bands immobilized on Im- 
mobilon were visualised by Ponceau red staining. Then blot slices were 
made and eluted by incubation for 3 h in 40% acetomtrrl and subse- 
quently centrifuged and lyophihzed to remove the volatile solvent. 
2.8. The effects of purified factor on cells in culture 
The effects of the protein blotting purified factor were studied on 
GHD cells. Proliferation was quantified with the MTT test which IS 
a calorimetric proliferation assay [14] (Sigma) for 12 h. A control using 
albumin purified identically was assessed. 
3. RESULTS 
In A431 cell membranes, EGF induces auto- 
phosphorylation of its receptor which is reflected in 
SDS-PAGE by an increase in the phosphorylation de- 
tected at 170 kDa. Unexpectedly, all CFs decreased 
phosphorylation detected at 170 kDa (Fig. 1A). Basal 
as well as EGF induced autophosphorylation of the 
receptor were inhibited. We quantified this inhibitory 
effect and compared the inhibitory effect observed in 
benign tumors (low grade astrocytomas: grade I and II) 
with that observed in malignant tumors (high grade 
astrocytomas: grade III and IV). The mean inhibition 
for basal phosphorylation of EGF-R was 90% in grade 
I-II and 50% for Grade III-IV (Significantly different 
P < 0.018). Previous treatment with trypsin and heat 
denaturation abolished the observed effect of CF on 
EGF-R autophosphorylation (data not shown). Vana- 
date as well as previous absorption with an anti-EGF-R 
antibody were without effect (data not shown). 
In some of the A431 cell membrane samples ana- 
lyzed, two molecular forms of EGF-R are observed at 
170 and 150 kDa. Previous studies have demonstrated 
that the 150 kDa form is a proteolytic product of the 
former [ 151 via a calcium-dependent protease. The 150 
kDa proteolytic product is known to be phosphorylated 
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Fig. 1. A. Inhibition of EGF-R phosphorylation in A431 membranes. Lane A (control), A43 1 membranes with EGF; lanes B to N, A43 1 membranes 
with EGF and CF 
Phosphorylation at 
associated-with low grade astrocytomas in F, G, J, L, N and with high grade astrocytoma in B, C, D. E. H, 1, K M. 
170 kDa is inhibited (arrow). B. Phosphotyrosme phosphorylation at 170 kDa in A 431 membrane with (+ EGF), without 
(- EGF) and in the presence of EGF and Cystic fluid (+ EGF + CF). 
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Fig. 2. Analysis of the inhibitory effect of EGF-R phosphorylatton in 
A 431 membranes in the presence of 8 fractions obtained after HPLC 
separation of crude CF on Superose 12. O.D. at 280 nm are indicated 
on the right, inhibition of EGF-R phosphorylation on the left, frac- 
tions volumes on the X axis. 
but lacks phosphotyrosine residues. When the CF fluid 
inhibitory effect was analysed by bidimensional electro- 
phoresis, only the 170 kDa form was inhibited (data not 
shown). Phosphoamino acid analysis was performed to 
investigate which phosphorylated residue was inhibited. 
Addition of CF to the A431 membrane phosphorylated 
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with EGF decreased the phosphotyrosine spot fourfold 
(Fig. 1B). Experiments were done on A431 and GHD 
cell lines in culture. A phosphorylation assay on whole 
cells in vitro demonstrated an inhibition of EGF-R 
phosphorylation with CF when compared to fetal calf 
serum, as was also observed on A431 isolated mem- 
branes. 
Eight fractions, eluted from a Superose 12 column 
(Fig. 2) were tested. An aliquot of the unconcentrated 
fraction was tested for its inhibitory activity on EGF-R 
phosphorylation. Dilution of the CF after HPLC sepa- 
ration was l/150. A peak of inhibitory activity com- 
pared with control in the absence of CF was identified 
in fraction 6 corresponding to a molecular weight of 
20-30 kDa. Inhibition of basal phosphorylation in the 
absence of EGF was 50%; in the presence of EGF inhi- 
bition was quantified as 75%. We also detected, in frac- 
tion 4 and 8 an ‘EGF-like’ activity. Fraction 1 corre- 
sponds to albumine one and fraction 8 is the fraction 
below 10 kDa. Purification was completed by prepara- 
tive protein blotting on 15% acrylamide gels according 
to the MW range identified by HPLC. Albumin, the 
main proteic component of CF was absorbed on a Hi- 
trap blue column to avoid electrophoretic streaking 
caused by to much protein. Proteic bands identified 
with Ponceau red were eluted and tested for their bio- 
logical effect on EGF-R phosphorylation. An inhib- 
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Fig. 3. Electra-elution of one CF after SDS-PAGE on 15% acrylamide gel. 10 slices were tested for the inhibitory effect. A. Crude CF. B. Silver 
staining of the inhibitory band detected at 18 kDa, purified after absorption of CF on blue Hitrap column and protein blotting (0.5 pg) on slice 
6. C. Inhibitory effect of EGF-R in A 431 membranes with each electro-eluate xpressed as a percentage of the control without eluted protein. 
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Fig. 4. Inhibition of EGF-R basal autophosphorylation i A431 membranes in the presence of different concentrations of inhibitor. 
itory activity was identified at 18 kDa (Fig. 3). A dose 
effect in inhibition was evaluated from 80 to 20% in the 
concentration range from 1 ,uM to 0.001 ,uM (Fig. 4). 
The purified factor was also tested in vivo on GHD 
cells. Proliferation was analyzed with the MTT test. 
Inhibition was observed from 100 ,uM to 0.1 PM in the 
range 90% to 30% (Fig. 5). Albumin did not induce any 
inhibition of proliferation. 
4. DISCUSSION 
Many transforming growth factors have been identi- 
fied in malignant effusions. Stimulation of the growth 
of cultured gliomas with cystic fluid has been reported 
[16] and ‘insulin growth factor like’ activity identified in 
CFs [ 171. The A43 1 cell line provides a good system for 
the identification of an ‘EGF-like’ activity. In view of 
such an autocrine growth regulation we tested A43 1 cell 
membranes with CFs. Paradoxically we found an inhib- 
itory activity of EGF-R autophosphorylation. CFs in- 
duced an inhibitory effect on both basal and EGF-in- 
duced EGF-R autophosphorylation in A431 cell mem- 
branes. This effect was observed in the 20 CFs analyzed. 
What is the nature of this inhibitory activity? Absence 
of the inhibition of phosphorylation of the 150 kDa 
proteolytic product of the EGF-R argues for the speci- 
ficity of this inhibitory effect. The effect on basal EGF- 
R autophosphorylation suggests the absence of compe- 
tition or sequestration of EGF by any CF component. 
This point is important to discuss because A43 1 cells are 
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Fig. 5. GHD proliferation in the presence of different concentrations of inhibitor after a 12-h incubation. Proliferation is quantified by the MTT 
test. 
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known to secrete truncated forms of the EGF-R with 
EGF binding activity. Moreover an EGF binding activ- 
ity has been identified in brain tissues [18]. The absence 
of the modification of CF inhibitory effect by previous 
immunoabsorption with an anti-EGF-R antibody sup- 
ports the absence of such an inhibitory factor. 
Phosphoamino acid analysis as well as the absence of 
inhibition of the 150 kDa proteolytic form indicate that 
the inhibitory effect acts through phosphotyrosine resi- 
dues. This could explain an effect on basal phosphoryl- 
ation. Vanadate did not influence the inhibitory effect 
which suggests that the related factor is not a tyrosine 
phosphatase. Tryptic and heat denaturation suggest 
that our anti-tyrosine kinase factor is of a proteic na- 
ture. Characterization by HPLC and preparative pro- 
tein blotting purification identified a 18 kDa MW fac- 
tor. It is interesting to observe that separation of the 
different components of crude CF by HPLC individual- 
izes ‘EGF-like’ activities which were blotted out by the 
strong inhibitory activity in crude CF. To our knowl- 
edge Mtillerian inhibiting substance (MIS) is the only 
known physiological factor isolated in vivo with an anti- 
tyrosine kinase activity. It is responsible for the regres- 
sion of Mtiller ducts in males during embryogenesis. 
This is probably the only known situation where a sub- 
stance inhibiting a proto-oncogene function generates 
tissular regression. MIS has been shown to inhibit tu- 
moral proliferation in vitro, especially growth of the 
A431 cell line [19]. Synthetic substances with anti-tyro- 
sine kinase function have been isolated and have re- 
cently been tested in vitro and in vivo with success as 
an anti-neoplastic agent [20]. However the molecular 
weight of MIS is different from that of the factor iden- 
tified in this study suggesting that it may be a new 
anti-tyrosine kinase factor. Further purification and mi- 
crosequencing procedures are necessary to clarify these 
issues. Persistance of this inhibitory effect at high dilu- 
tions shows its effectiveness and suggests its biological 
role. Moreover, the strongest effect is observed with 
non-diluted samples of CF which represents the pa- 
thological ‘in vivo’ situation. Its persistence on whole 
cells in culture argues for possible in vivo involvement. 
The finding of a more important inhibitory effect in low 
grade astrocytoma compared to the more malignant 
ones suggests that this factor could be involved in the 
tumoral progression of astrocytoma. Furthermore, 
EGF-responsive stem cells have recently been isolated 
from adult mammalian central nervous systems [21] 
which focused on the regulatory factors involved in the 
local inhibition of these cells. The factor identified in 
our study may be a candidate for inhibition of local 
proliferation of these cells in the non-tumoral adult cen- 
tral nervous system. 
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